Oncogeriatry is the clinical discipline concerned with the management of elderly cancer patients. It is based on a global oncological and geriatric approach to the health status of patients. Oncogeriatry has been widely adopted throughout the world, but the approaches used and the organisational solutions provided are complex and varied. Based on the French experience of a centralised health system, the different aspects are discussed: clinical management, organisation, clinical research and information. At a European level, the best approach seems to be a partnership between the International Society of Geriatric Oncology and the Elderly Task Force of the European Organisation on Research and Treatment of Cancer. This co-operation ensures comprehensive information on oncogeriatric programmes, clinical research and teaching programmes, thus enhancing the effectiveness of the oncogeriatric approach.
Ageing is associated with progressive but extremely uneven decline of functional reserves and a reduction of adaptability. Geriatricians, who commonly handle the highly heterogeneous process of ageing, have devised a comprehensive multidisciplinary assessment tool called 'comprehensive geriatric assessment' (CGA), in which all aspects of older individuals are considered and all resources and abilities are listed. Based on this appraisal, geriatricians can elaborate and co-ordinate an effective care plan with interventions tailored to each individual's problems. 2 Health authorities and health professionals must face the expanding challenge of the management of elderly cancer patients.
This challenge has not been anticipated and the ever-increasing number of elderly patients suffering from cancer will result in higher costs of medical and social care. However, the costeffectiveness of cancer management in the elderly remains to be evaluated both at country level, because health organisations are different across European countries, 3 and at the European level.
Cost-effective strategies for preventing and detecting cancer early should also be considered. 4 Two important observations are that elderly patients have been critically undertreated in the past, 5 but that their willingness to receive treatment is evident. 6 The recent demographic trend has led to the emergence of a new medical discipline called oncogeriatry and to the worldwide development of oncogeriatric programmes dedicated to the management of elderly cancer patients. 7 This article focuses on the principal areas of development of oncogeriatry through a discussion of the French experience, since it is impossible to collect homogeneous data on the organisation of oncogeriatry in the different European countries. 8 The objectives of this article are:
• to collect basic epidemiological information;
• to focus on the concept of oncogeriatry;
• to define the different approaches of oncogeriatric practice;
• to identify the different possible forms of organisation of oncogeriatric programmes;
• to review the different types of clinical research programmes;
• to make a survey of scientific societies of oncogeriatry with a particular focus on their objectives; and
• to give some indications on possible future developments in oncogeriatry.
to calculate cancer incidence in women and men living in European countries on the basis of age.
10 Figure 1 shows that cancer incidence increases constantly with age and is higher in men than in women. It is possible to model cancer incidence in the next five, 10 and 20 years in the different cohorts based on date of birth and age. 11 A comparison of these extrapolations with observed French data (see Figure 2) demonstrates that the number of elderly patients likely to have cancer is constantly increasing.
The Concept of Oncogeriatry
Once one has become aware of the multidimensional nature of ageing, questions arise in determining the optimal approach for the management of elderly cancer patients. Inclusion of geriatric criteria in cancer protocols is universally proposed. Although eligibility criteria for prospective clinical trials generally allow the inclusion of patients 70 years of age and over, elderly patients are under-represented in clinical studies. 12 Investigators usually integrate some CGA tools (sometimes referred to as 'abbreviated CGA') 13 when designing clinical trials. 14 CGA explores different aspects of the elderly population:
• dependence (activities of daily living and instrumental activities of daily living scales);
• cognitive domain (Mini Mental State Examination);
• emotional condition (geriatric depression scale);
• co-morbidity (cumulative illness rating scale-geriatric or
Charlson's scale);
• nutrition (mini nutritional assessment [MNA]);
• polypharmacy (number of drugs); and
• geriatric syndrome identification.
There are many limitations to the use of the different geriatric No screening tool has yet been validated in elderly cancer patients.
The objective of screening is to select patients who could benefit from CGA: frail elderly patients and those assessed as 'vulnerable' (there is no definitive definition of vulnerability; this group represents patients with possibly reversible ageing-related problems). 16 Rapid changes should occur in the near future based on the growing number of teams involved in this field of research and on the dynamism of SIOG.
Several retrospective studies are using multivariate analysis to identify the strongest factors for screening frailty. Finally, CGA is used to determine geriatric management and intervention programmes. The possible impact of geriatric interventions on cancer outcome is unknown, even though some small prospective studies suggest positive effects. 19, 20 Nowadays the concept of oncogeriatry is shared by all oncological and geriatric communities around the world. It is interesting to engage in a semantic discussion about the term: is it actually indicate that it is a sub-speciality of oncology (similar to gastrointestinal oncology), whereas 'oncogeriatry' indicates a merge between oncology and geriatrics. We would rather use the second term, but its meaning should be made clear when used in the organisational setting, as the concept will be developed later. 7, 16, 21 In addition, the practice of geriatric oncology varies among countries.
Different Approaches to Oncogeriatry
There are different approaches to cancer management in older adults. Oncologists, particularly medical oncologists, have adapted the oncological approach to this group. This is the approach used by the pioneers of geriatric oncology, Monfardini in Italy 22 and Balducci 23 in the US. The development of geriatric oncology has been based on the introduction of geriatric concepts, such as dependence, autonomy, malnutrition, etc. Next, the concept of frailty was introduced, 16 but no precise definition is available. There have been two consequences of this approach. The first is that the geriatric approach mainly involves the use of screening tools, which are likely to be as sophisticated as Kanofsky indices. 24 The second is that these screening tools identify co-variables that can be introduced in prognostic studies and used as inclusion/exclusion criteria in prospective studies. The advantage of this situation is that it has helped popularise the geriatric approach and stimulated clinical research. The disadvantage is the risk of misunderstanding the global nature of the health status of older adults. Consequently, it seems that specific geriatric interventions have not been sufficiently considered, both in routine treatments and in research applications. This initial, purely oncological, approach taken by the pioneers has rapidly evolved towards a shared management of elderly cancer patients by both oncologists and geriatricians.
On the basis of previous practice, we have attempted to build our own geriatric oncology programme with an equal participation of oncologists and geriatricians for the management of older adults with cancer. With this approach, geriatric tools are only used as screening tests. CGA has become the routine procedure to evaluate the health status of older adults, and geriatric interventions are part of the management of these elderly cancer patients. The consequence of this approach is that the procedure is time-consuming; however, it is certainly not mandatory for all patients. Moreover, it is difficult to disseminate in the community and to use in a clinical research setting. These two conceptions of oncogeriatry have given rise to different types of organisation.
Different Organisation Models for Oncogeriatry
A specific oncogeriatric programme has been developed in France over the past five years. It originated in 2003 with the cancer plan launched by President Jacques Chirac and the French government. 25 At the same time an old age plan was designed to organise the management of elderly patients in France.
When the French National Cancer Institute was created, a specific oncogeriatric committee was mandated to develop the concept in
France. 26 The committee decided to develop Pilot Units of OncoGeriatry (UPCOG). Two calls for applications were issued in 2005 and 2006. In total, 15 UPCOG were funded across the country (see Figure 3) . The objectives of these UPCOG were to develop research, education, information and clinical management of elderly patients.
All UPCOG received a two-year grant to initiate the project and were evaluated after one and two years. After the two-year evaluation, they Nevertheless, it has been possible to observe that, as no specific organisational structure was required for submitting an application (the only prerequisite was the collaboration of oncologists and geriatricians), different organisational solutions have been proposed.
This exactly reflects the conclusions of a survey published by
Monfardini on behalf of the SIOG task force. 27 The clinical practice of 58 SIOG members working in different centres in different countries around the world was analysed. All participants had identified oncogeriatry as their area of specialisation. CGA was performed in 60% of cases. The implementation of a geriatric oncology programme (GOP) was reported in 21 centres: 85% oncology units and 15% geriatric departments. In most GOPs, case discussion conferences dedicated to the management of elderly cancer patients were scheduled. The multidisciplinary team involved in the activity included medical oncologists, geriatricians, nurses, pharmacists and social workers. Fellowships in oncogeriatry were offered in almost half of the GOPs. Over 60% of the centres were willing to recruit patients to clinical trials, while the proportion of cases actually included was only 20%.
The SIOG task force suggested further developments with a stepwise progression as follows:
• promotion of geriatric oncologists with training in both medical oncology and geriatrics capable of performing CGA; 
National and European Oncogeriatric Organisations
One may consider two specific aspects of organisations: clinical research groups or networks and scientific societies for oncogeriatry.
Clinical Research
In In Europe, national geriatric clinical research groups were established in different countries, such as Italy, a long time ago, 29, 30 and more recently in the UK 31 and Germany. 32 However, a comprehensive survey of clinical trials in Europe and even the US is very difficult. In the US, the National Cancer Institute database does not allow the identification of clinical trials specifically dedicated to elderly patients.
In Europe, a survey performed by SIOG 33 has identified only six such trials, three of which are in the UK, but they are not accessible through the Medical Research Council website. Nevertheless, international ad hoc groups, such as the PACE group, have emerged. 28 The only formalised co-operative group is the European Organisation on
Research and Treatment of Cancer (EORTC) task force, which is only accessible on the EORTC website to registered practitioners. The group is composed of around 50 investigators from 18 European countries.
It is still in the process of formalising its statutes and activities, as well as building its finances. A number of strategies have already emerged:
• to perform retrospective studies on the populations of elderly patients included in EORTC trials from different groups, with a focus on toxicities;
• to introduce some form of geriatric assessment in current trials conducted by EORTC clinical research groups;
• to collaborate with established organ-orientated groups to perform trials specifically designed for elderly patients (for example a study of a combination of chemotherapy and targeted treatment in breast cancer); and
• to perform specific trials within the group, such as testing new drugs in patients with lung cancer.
The group has also been discussing the possibility of developing translational research and the choice of geriatric assessment tools to be introduced in clinical trials, which is one of the major issues to be addressed. This leads to some thoughts. There is a concern about competition between the interests of organ-orientated and age- cancer. This is still a work in progress.
Scientific Societies
The French Society of Oncogeriatry, which is affiliated to SIOG, was founded four years ago. It organises an annual meeting but does not support clinical trials. There is currently an attempt to link this society to 
Perspectives
The first concern of the authors when preparing this article was the difficulty of collecting information on oncogeriatry in Europe. • to provide public information targeted to patients, their families and healthcare professionals;
• to compile a list of national societies with contact information;
• to identify clinical trials conducted within the European network but also through national organisations;
• to provide information on basic and translational research programmes;
• to provide information on teaching programmes at both national and European levels; and
• to implement SIOG guidelines. 33 The feeling of the authors is that oncogeriatry is an immature 
